Pharma BD Deal Intelligence
On June 1, 2026, Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up to $2.65 billion, comprising a $1.55 billion upfront payment and up to $1.1 billion in regulatory and commercial milestones. The transaction transfers global rights to sevasemten, an orally administered fast skeletal myosin inhibitor in a pivotal Becker muscular dystrophy cohort and a Phase 2 Duchenne muscular dystrophy study, along with related IP, regulatory filings and clinical data. Milestones include up to $200 million tied to Becker labeling, $600 million on Duchenne U.S. approval, and $300 million on annual U.S. net sales exceeding $550 million. The deal is expected to close in Q3 2026 subject to regulatory clearance; Edgewise retains its cardiovascular pipeline.